The Pharmaceutical Journal
Vol 274 No 7345 p445
16 April 2005

This article
Reprint   Photocopy

  Acrobat Reader

News summary

MHRA rules that Wyeth undermined the CSM

The Medicines and Healthcare products Regulatory Agency has upheld a complaint against Wyeth regarding Efexor (venlafaxine).

The complaint was that representatives of Wyeth had distributed material that cast doubt on the validity of the Committee on Safety of Medicines recommendation to restrict the use of Efexor, openly questioned the CSM’s safety advice and misquoted National Institute for Clinical Excellence guidance to favour Efexor. Wyeth has withdrawn the misleading information pack and has carried out its own investigation into this complaint and reviewed its procedures.